MedTrace Logo

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

NCT01196975 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1707

Last updated 2018-09-21

Study results available
· View outcomes & findings →

Summary

This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines.

This study will also evaluate the lot-to-lot consistency of three vaccine lots.

Conditions

Interventions

BIOLOGICAL

Quadrivalent seasonal influenza vaccine GSK2282512A

Single intramuscular dose

BIOLOGICAL

FluLavalTM-VB

Single intramuscular dose

BIOLOGICAL

FluLavalTM-YB

Single intramuscular dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-01
Primary Completion
2011-01-25
Completion
2011-06-24

Countries

  • United States
  • Canada
  • Mexico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196975 on ClinicalTrials.gov